Log in for full access to this activity, if you are registered.

Registration Options

Activity Dates: 09/15/2014 - 02/27/2015

This course is closed. Please look for other available products in CPNP University.

Target Audience

This home-study course serves as an educational tool for pharmacists and other pharmacists and health care providers seeking advanced education in patient management, information management, and health policy and practice management in the field of psychiatric pharmacy.

Course Requirements

To satisfactorily complete the Literature Analysis and receive 10.0 contact hours of ACPE credit, candidates must meet the following requirements:

  1. Abide by a confidentiality and honesty statement requiring individual completion of the Recertification education.
  2. Complete an online assessment by the deadline of February 27, 2015.
  3. Meet the minimum passing score of 76% for the examinations as determined by a panel of experts.
  4. Partial credit is not available for individual topics within the Literature Analysis programming; it is either all 10 hours of Literature Analysis programming credit or none.

You will proceed through the following steps to satisfactorily complete this course:

  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date. (login first)
  • Complete the evaluation at the end of the activity. (login first)
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor. (login first)

Your ACPE credit will be submitted directly to CPE Monitor within 48 hours after successful completion of the examination as long as you  you have provided the relevant information in your profile.

Learning Objectives

2014 Literature Analysis Articles

  • Headache/Migraine (2 hours)

    Rizzoli PB. Acute and Preventive Treatment of Migraine. Continuum Lifelong Learning. Neurol. 2012;18(4):764–782. ACPE: 1.0 contact hour; Application: #0284-0000-14-047-H01-P

    Silberstein SD, et al. Randomized, placebo-controlled trial of propranolol added to topoiramate in chronic migraine. Neurology 2012; 78:976-984. ACPE: 1.0 contact hour; Application: #0284-0000-14-047-H01-P

    Holland S, Silberstein SD, Freitag F, et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Neurology.2012;78:1346–1353. ACPE: 1.0 contact hour; Application: #0284-0000-14-047-H01-P

  • Mood Disorders (2 hours)

    Elderon L and Whooley MA. Depression and cardiovascular disease. Prog Cardiovasc Dis; 2013;55:511-523. ACPE: 1.0 contact hour; Application: #0284-0000-14-048-H01-P

  • Gibertini, M., Nations, K., Whitaker, J. Obtained effect size as a function of sample size in approved antidepressants: A real-world illustration in support of better trial design. International Clinical Psychopharmacology, 2012, Vol 27, No 2, 100-106.
    AND
    Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, et al. Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 2012;37:1526-1533. ACPE: 1.0 contact hour; Application: #0284-0000-14-048-H01-P

  • Schizophrenia (2 hours)

    Franz M, Fritz M, Gallhofer B, Meyer T. QLiS-development of a schizophrenia-specific quality-of-life scale. Health Qual Life Outcomes. 2012; 10: 61. ACPE: 1.0 contact hour; Application: #0284-0000-14-049-H01-P

    Patten SB, Remillard A, Phillips L, Modgill G, Szeto ACh, Kassam A, Gardner DM. Effectiveness of contact based-education for reducing mental illness-related stigma in pharmacy students. BMC Med Educ. 2012,12:120. doi: 10.1186/1472-6920-12-120. ACPE: 1.0 contact hour; Application: #0284-0000-14-049-H01-P

  • Social Anxiety Disorder (2 hours)

    Blanco C, Bragdon LB, Schneier FR, Liebowitz MR. The evidence-based pharmacotherapy of social anxiety disorder. Int J Neuropsychopharmacol. 2013;16(1):235-49. ACPE: 1.0 contact hours; Application: #0284-0000-14-051-H01-P

    National Institute for Health and Care Excellence. Social anxiety disorder: recognition, assessment and treatment of social anxiety disorder. (Clinical guideline 159.) 2013. http://guidance.nice.org.uk/CG159. ACPE: 1.0 contact hour; Application: #0284-0000-14-051-H01-P

  • Suicidal Ideation (2 hours)

    Nock MK, Green JG, Hwang I, et al.  Prevalence, Correlates and Treatment of Lifetime Suicidal Behavior Among Adolescents: Results from the National Comorbidity Survey Replication Adolescent Supplement. JAMA Psychiatry 2013;70(3):300-310. ACPE: 1 contact hour; Application: #0284-0000-14-054-H01-P

    Wasserman D, Rihmer Z, Rujescu D, et al.  The European Psychiatric Association guidance on suicide treatment and prevention. European Psychiatry 2012; 27: 129-141. ACPE: 1 contact hour; Application: #0284-0000-14-054-H01-P

 

Continuing Education Credit and Disclosures

Activity Dates: 09/15/2014 - 02/27/2015
ACPE Contact Hours: 10.0
ACPE Numbers: 0284-0000-14-047-H01-P (Application), 0284-0000-14-048-H01-P (Application), 0284-0000-14-049-H01-P (Application), 0284-0000-14-051-H01-P (Application), 0284-0000-14-054-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPE

The College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Literature Analysis product is an application-based program approved for 10.0 ACPE contact hours. To receive ACPE credit, pharmacists completing this programming are required to complete an evaluation of the course as well as pass an online examination.

CPNP will report credits earned into CPE Monitor. ACPE transcripts reflecting CPE Monitor reporting are available at cpnp.org/mycpnp/transcript/acpe.

Grant Support

This activity is supported by an educational grant from Sunovion Pharmaceuticals, Inc. and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.